SANGOMA TECHNOLOGIES CORP (SANG) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:SANG • CA80100R4089

4.73 USD
+0.05 (+0.96%)
Last: Feb 9, 2026, 08:00 PM
Fundamental Rating

3

Overall SANG gets a fundamental rating of 3 out of 10. We evaluated SANG against 48 industry peers in the Communications Equipment industry. SANG may be in some trouble as it scores bad on both profitability and health. SANG is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • In the past year SANG has reported negative net income.
  • In the past year SANG had a positive cash flow from operations.
  • SANG had negative earnings in 4 of the past 5 years.
  • SANG had a positive operating cash flow in each of the past 5 years.
SANG Yearly Net Income VS EBIT VS OCF VS FCFSANG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

1.2 Ratios

  • The Return On Assets of SANG (-1.61%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -2.16%, SANG is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
ROA -1.61%
ROE -2.16%
ROIC N/A
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
SANG Yearly ROA, ROE, ROICSANG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10 -20 -30

1.3 Margins

  • SANG's Gross Margin of 69.22% is amongst the best of the industry. SANG outperforms 91.67% of its industry peers.
  • In the last couple of years the Gross Margin of SANG has remained more or less at the same level.
  • SANG does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
SANG Yearly Profit, Operating, Gross MarginsSANG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

3

2. Health

2.1 Basic Checks

  • SANG does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SANG has been reduced compared to 1 year ago.
  • SANG has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, SANG has an improved debt to assets ratio.
SANG Yearly Shares OutstandingSANG Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
SANG Yearly Total Debt VS Total AssetsSANG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of 1.11, we must say that SANG is in the distress zone and has some risk of bankruptcy.
  • SANG has a Altman-Z score of 1.11. This is comparable to the rest of the industry: SANG outperforms 45.83% of its industry peers.
  • SANG has a debt to FCF ratio of 1.93. This is a very positive value and a sign of high solvency as it would only need 1.93 years to pay back of all of its debts.
  • SANG's Debt to FCF ratio of 1.93 is fine compared to the rest of the industry. SANG outperforms 64.58% of its industry peers.
  • SANG has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
  • SANG has a Debt to Equity ratio (0.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.93
Altman-Z 1.11
ROIC/WACCN/A
WACC8.46%
SANG Yearly LT Debt VS Equity VS FCFSANG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.3 Liquidity

  • SANG has a Current Ratio of 0.87. This is a bad value and indicates that SANG is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of SANG (0.87) is worse than 91.67% of its industry peers.
  • A Quick Ratio of 0.72 indicates that SANG may have some problems paying its short term obligations.
  • SANG's Quick ratio of 0.72 is on the low side compared to the rest of the industry. SANG is outperformed by 89.58% of its industry peers.
Industry RankSector Rank
Current Ratio 0.87
Quick Ratio 0.72
SANG Yearly Current Assets VS Current LiabilitesSANG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 23.81% over the past year.
  • Looking at the last year, SANG shows a decrease in Revenue. The Revenue has decreased by -4.28% in the last year.
  • The Revenue has been growing by 19.31% on average over the past years. This is quite good.
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-4.28%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-12.96%

3.2 Future

  • The Earnings Per Share is expected to grow by 53.23% on average over the next years. This is a very strong growth
  • SANG is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.32% yearly.
EPS Next Y-21.2%
EPS Next 2Y53.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-12.47%
Revenue Next 2Y-4.32%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SANG Yearly Revenue VS EstimatesSANG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
SANG Yearly EPS VS EstimatesSANG Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -1 -2 -3

3

4. Valuation

4.1 Price/Earnings Ratio

  • SANG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Based on the Price/Forward Earnings ratio of 90.64, the valuation of SANG can be described as expensive.
  • Based on the Price/Forward Earnings ratio, SANG is valued a bit more expensive than the industry average as 62.50% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of SANG to the average of the S&P500 Index (27.86), we can say SANG is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 90.64
SANG Price Earnings VS Forward Price EarningsSANG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

  • SANG's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SANG is cheaper than 100.00% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, SANG is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.99
EV/EBITDA 4.5
SANG Per share dataSANG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SANG's earnings are expected to grow with 53.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y53.23%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

  • No dividends for SANG!.
Industry RankSector Rank
Dividend Yield 0%

SANGOMA TECHNOLOGIES CORP

NASDAQ:SANG (2/9/2026, 8:00:02 PM)

4.73

+0.05 (+0.96%)

Chartmill FA Rating
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryCommunications Equipment
Earnings (Last)02-04
Earnings (Next)05-06
Inst Owners35.19%
Inst Owner Change1.61%
Ins Owners27.37%
Ins Owner ChangeN/A
Market Cap156.75M
Revenue(TTM)236.69M
Net Income(TTM)-5.44M
Analysts82
Price Target8.18 (72.94%)
Short Float %0.47%
Short Ratio29.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)285.64%
Min EPS beat(2)-23.76%
Max EPS beat(2)595.05%
EPS beat(4)1
Avg EPS beat(4)85.56%
Min EPS beat(4)-197.03%
Max EPS beat(4)595.05%
EPS beat(8)2
Avg EPS beat(8)30.1%
EPS beat(12)4
Avg EPS beat(12)5.37%
EPS beat(16)6
Avg EPS beat(16)-259.19%
Revenue beat(2)1
Avg Revenue beat(2)-0.06%
Min Revenue beat(2)-0.46%
Max Revenue beat(2)0.34%
Revenue beat(4)1
Avg Revenue beat(4)-2.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)0.34%
Revenue beat(8)2
Avg Revenue beat(8)-1.95%
Revenue beat(12)3
Avg Revenue beat(12)-2.49%
Revenue beat(16)6
Avg Revenue beat(16)-0.19%
PT rev (1m)-2.71%
PT rev (3m)2.5%
EPS NQ rev (1m)26.14%
EPS NQ rev (3m)-8.33%
EPS NY rev (1m)1.82%
EPS NY rev (3m)-50%
Revenue NQ rev (1m)-0.06%
Revenue NQ rev (3m)0.63%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 90.64
P/S 0.69
P/FCF 5.99
P/OCF 4.53
P/B 0.62
P/tB N/A
EV/EBITDA 4.5
EPS(TTM)-0.16
EYN/A
EPS(NY)0.05
Fwd EY1.1%
FCF(TTM)0.79
FCFY16.69%
OCF(TTM)1.04
OCFY22.07%
SpS6.86
BVpS7.59
TBVpS-0.81
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -1.61%
ROE -2.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.22%
FCFM 11.51%
ROA(3y)-3.39%
ROA(5y)-6.47%
ROE(3y)-5.4%
ROE(5y)-10.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.76%
GM growth 5Y1.11%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 1.93
Debt/EBITDA 0.67
Cap/Depr 18.9%
Cap/Sales 3.71%
Interest Coverage N/A
Cash Conversion 81.28%
Profit Quality N/A
Current Ratio 0.87
Quick Ratio 0.72
Altman-Z 1.11
F-Score5
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)22.92%
Cap/Depr(5y)19.53%
Cap/Sales(3y)4.2%
Cap/Sales(5y)3.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-21.2%
EPS Next 2Y53.23%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-4.28%
Revenue growth 3Y1.79%
Revenue growth 5Y19.31%
Sales Q2Q%-12.96%
Revenue Next Year-12.47%
Revenue Next 2Y-4.32%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-112.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2299.66%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.51%
FCF growth 3Y27.36%
FCF growth 5Y36.51%
OCF growth 1Y12.7%
OCF growth 3Y25.66%
OCF growth 5Y36.31%

SANGOMA TECHNOLOGIES CORP / SANG FAQ

What is the fundamental rating for SANG stock?

ChartMill assigns a fundamental rating of 3 / 10 to SANG.


What is the valuation status for SANG stock?

ChartMill assigns a valuation rating of 3 / 10 to SANGOMA TECHNOLOGIES CORP (SANG). This can be considered as Overvalued.


What is the profitability of SANG stock?

SANGOMA TECHNOLOGIES CORP (SANG) has a profitability rating of 3 / 10.


How financially healthy is SANGOMA TECHNOLOGIES CORP?

The financial health rating of SANGOMA TECHNOLOGIES CORP (SANG) is 3 / 10.